Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | LTA4H | P09960 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4456543 | 0.95 | MCL1 (0.54) | MCL1XDHRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4460360 | 0.95 | LTA4H (0.47) | MCL1XDHRAB9ANPC1LTA4H | |
| SCHEMBL3270671 | 0.93 | MAOA (0.46) | MCL1XDHRAB9ANPC1LTA4H | |
| SCHEMBL4680696 | 0.93 | MCL1 (0.48) | MCL1XDHRAB9ANPC1LTA4H | |
| SCHEMBL4460188 | 0.93 | NPC1 (0.45) | MCL1XDHRAB9ANPC1LTA4H | |
| SCHEMBL4456749 | 0.93 | PRMT5 (0.43) | MCL1XDHRAB9ANPC1LTA4H | |
| SCHEMBL4455245 | 0.93 | NPC1 (0.50) | MCL1XDHRAB9ANPC1LTA4H | |
| Hydrochloric Acid SCHEMBL4461345 | 0.92 | XDH (0.45) | MCL1XDHRAB9ANPC1LTA4H | |
| SCHEMBL4680834 | 0.91 | MAOB (0.47) | MCL1XDHRAB9ANPC1LTA4H | |
| SCHEMBL4455715 | 0.91 | MAOB (0.47) | MCL1SMN1; SMN2MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638943-B1 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | SOD CONSEILS RECH APPLIC (FR) | 2008-08-06 | — | — | EP | claimed |
| JP-2007501267-A | — | — | 2007-01-25 | — | — | JP | claimed |
| EP-1638943-A2 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-03-29 | — | — | EP | claimed |
| WO-2004106307-A2 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-12-09 | — | — | WO | claimed |
| US-8188133-B2 | Imidazole derivatives, preparation and user thereof as medicine | IPSEN PHARMA S.A.S. (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188133-B2 | Imidazole derivatives, preparation and user thereof as medicine | IPSEN PHARMA S.A.S. (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20090186930-A1 | NOVEL IMIDAZOLE DERIVATIVES, PREPARATION AND USER THEREOF AS MEDICINE | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-07-23 | — | — | US | disclosed |
| US-20090186930-A1 | NOVEL IMIDAZOLE DERIVATIVES, PREPARATION AND USER THEREOF AS MEDICINE | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-07-23 | — | — | US | disclosed |
| EP-1638943-B1 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | SOD CONSEILS RECH APPLIC (FR) | 2008-08-06 | — | — | EP | disclosed |
| EP-1638943-A2 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004106307-A2 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186930-A1 | NOVEL IMIDAZOLE DERIVATIVES, PREPARATION AND USER THEREOF AS MEDICINE | CYP51A1, IKZF3, MIF | MCL1 86/4885XDH 282/4885RAB9A 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.